Intervention

denosumab

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 6 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials6

Recruiting0

Common conditions25

Lead sponsors shown4

Clinical trials

6 shown

Denosumab for Glucocorticoid-treated Children With Rheumatic DisordersNCT02418273 · 2019-08-01

WITHDRAWN

Presurgical Trial of Denosumab in Breast CancerNCT02900469 · 2016-10-01

COMPLETED

AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) TreatmentNCT01973569 · 2013-10-01

COMPLETED

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumNCT00896454 · 2009-11-16

COMPLETED

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate CancerNCT00321620 · 2006-04-01

COMPLETED

Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid ArthritisNCT00095498 · 2004-08-11

COMPLETED

Common conditions

Leading sponsors

Amgen 3 Daiichi Sankyo 1 Indiana University 1 NYU Langone Health 1

Trial status mix

COMPLETED5

WITHDRAWN1

Phase mix

PHASE23

EARLY_PHASE11

NA1

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.